公开(公告)号：WO2013039989A1

公开(公告)日：2013-03-21

申请号：PCT/US2012/054786

申请日：2012-09-12

申请人： PDS BIOTECHNOLOGY CORPORATION ,  BEDU-ADDO, Frank ,  CONN, Gregory ,  JACOBSON, Eric ,  MERCER, Carol ,  JOHNSON, Kenya

发明人： BEDU-ADDO, Frank ,  CONN, Gregory ,  JACOBSON, Eric ,  MERCER, Carol ,  JOHNSON, Kenya

IPC分类号： A61K39/00 ,  A61K45/00

CPC分类号： A61K39/39 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/585 ,  A61K2039/6018 ,  C12N2710/20034

摘要： The present disclosure provides vaccine formulations comprising at least one peptide antigen assembly and at least one adjuvant. The disclosure also provides methods of inducing an immune response in a mammal and methods of treating a disease in a mammal utilizing the vaccine formulations.

摘要翻译： 本公开提供了包含至少一种肽抗原组合物和至少一种佐剂的疫苗制剂。 本公开还提供了在哺乳动物中诱导免疫应答的方法和使用疫苗制剂治疗哺乳动物疾病的方法。

公开(公告)号：WO2014047533A1

公开(公告)日：2014-03-27

申请号：PCT/US2013/061132

申请日：2013-09-23

申请人： BEDU-ADDO, Frank ,  JACOBSON, Eric ,  JOHNSON, Kenya

发明人： BEDU-ADDO, Frank ,  JACOBSON, Eric ,  JOHNSON, Kenya

IPC分类号： A61K39/145 ,  A61K39/00 ,  A61P37/00

CPC分类号： A61K39/39 ,  A61K39/0002 ,  A61K39/0005 ,  A61K39/02 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/70 ,  C12N2760/16034 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y02A50/412

摘要： The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.

摘要翻译： 本公开提供了包含至少一种佐剂和至少一种抗原的疫苗组合物，其中所述佐剂是阳离子脂质。 本公开还提供了治疗哺乳动物疾病的方法，预防哺乳动物疾病的方法，以及使用疫苗组合物在哺乳动物中进行抗原交叉表达以诱导体液免疫应答和细胞免疫应答的方法。 各种抗原的交叉表现可以通过具有佐剂性质的阳离子脂质配制特异性抗原来实现。

公开(公告)号：WO2008116078A2

公开(公告)日：2008-09-25

申请号：PCT/US2008/057678

申请日：2008-03-20

申请人： PDS BIOTECHNOLOGY CORPORATION ,  CHEN, Weihsu ,  YAN, Weili ,  HUANG, Leaf ,  CONN, Gregory ,  BEDU-ADDO, Frank ,  TONEY, Kenya

发明人： CHEN, Weihsu ,  YAN, Weili ,  HUANG, Leaf ,  CONN, Gregory ,  BEDU-ADDO, Frank ,  TONEY, Kenya

IPC分类号： A61K38/04

CPC分类号： A61K31/231 ,  A61K31/14 ,  A61K31/20 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61K47/646 ,  A61K2039/55555 ,  C07C219/06

摘要： The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.

摘要翻译： 本发明提供了使用单独或与抗原组合的阳离子脂质来刺激免疫应答的组合物和方法。

公开(公告)号：WO2009129227A1

公开(公告)日：2009-10-22

申请号：PCT/US2009/040500

申请日：2009-04-14

申请人： PDS BIOTECHNOLOGY CORPORATION ,  VASIEVICH, Elizabeth, Ann ,  CHEN, Weihsu ,  TONEY, Kenya ,  CONN, Gregory ,  BEDU-ADDO, Frank ,  HUANG, Leaf

发明人： VASIEVICH, Elizabeth, Ann ,  CHEN, Weihsu ,  TONEY, Kenya ,  CONN, Gregory ,  BEDU-ADDO, Frank ,  HUANG, Leaf

IPC分类号： A61K31/685

CPC分类号： A61K31/685

摘要： A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R 1 is a quaternary ammonium group, Y 1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R 2 and R 3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.

摘要翻译： 一种用于活化免疫细胞的组合物和方法，或在受试者中诱导免疫应答，包括包含至少一种手性阳离子脂质的组合物。 一个实施方案中的手性阳离子脂质包含具有由式（I）表示的结构的非甾类阳离子脂质; 其中在R1是季铵基，Y1是选自烃链，酯，酮和肽的间隔物，C *是手性碳，R2和R3独立地选自饱和脂肪酸，不饱和的 脂肪酸，酯连接的烃，磷 - 二酯及其组合。

公开(公告)号：WO2017083820A9

公开(公告)日：2017-05-18

申请号：PCT/US2016/061829

申请日：2016-11-14

申请人： PDS BIOTECHNOLOGY CORPORATION ,  BEDU-ADDO, Frank ,  CONN, Greg ,  GANDHAPUDI, Siva K. ,  KEOUGH, Martin ,  MOHS, Angela ,  PATEL, Ritu ,  SINGH, Shweta ,  WARD, Martin ,  WOODWARD, Jerold

发明人： BEDU-ADDO, Frank ,  CONN, Greg ,  GANDHAPUDI, Siva K. ,  KEOUGH, Martin ,  MOHS, Angela ,  PATEL, Ritu ,  SINGH, Shweta ,  WARD, Martin ,  WOODWARD, Jerold

IPC分类号： C12N5/0784 ,  C07K17/04 ,  C12P21/00

摘要： The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

公开(公告)号：WO2017083820A1

公开(公告)日：2017-05-18

申请号：PCT/US2016/061829

申请日：2016-11-14

申请人： PDS BIOTECHNOLOGY CORPORATION ,  BEDU-ADDO, Frank ,  CONN, Greg ,  GANDHAPUDI, Siva K. ,  KEOUGH, Martin ,  MOHS, Angela ,  PATEL, Ritu ,  SINGH, Shweta ,  WARD, Martin ,  WOODWARD, Jerold

发明人： BEDU-ADDO, Frank ,  CONN, Greg ,  GANDHAPUDI, Siva K. ,  KEOUGH, Martin ,  MOHS, Angela ,  PATEL, Ritu ,  SINGH, Shweta ,  WARD, Martin ,  WOODWARD, Jerold

IPC分类号： C12N5/0784 ,  C07K17/04 ,  C12P21/00

CPC分类号： C12N5/0639 ,  A61K35/14 ,  C12N2500/36 ,  C12N2501/22 ,  C12P21/00

摘要： The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

摘要翻译： 本发明涵盖了在离体树突细胞疗法中使用某些类型的脂质，包括阳离子脂质。 阳离子脂质分别通过MHC I类和II类递呈途径增强了树突细胞对CD8 +和CD4 + T细胞的抗原摄取，处理和呈递处理的抗原。 通过树突状细胞通过阳离子脂质摄取抗原导致肿瘤中免疫抑制调节性T细胞群的显着降低和肿瘤靶向细胞毒性T细胞的显着增加。 调节性T细胞的丧失和肿瘤特异性细胞毒性细胞的增加有利于有效消除肿瘤。